Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PRAX - Praxis Precision Medicines, Inc.


IEX Last Trade
76.025
0.145   0.191%

Share volume: 3,019
Last Updated: Fri 27 Dec 2024 08:30:24 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%

$75.88
0.15
0.19%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
0.84%
1 Month
-1.55%
3 Months
35.26%
6 Months
96.73%
1 Year
240.53%
2 Year
128.71%
Key data
Stock price
$76.02
P/E Ratio 
0.00
DAY RANGE
$75.09 - $78.25
EPS 
$0.00
52 WEEK RANGE
$22.65 - $86.93
52 WEEK CHANGE
$251.08
MARKET CAP 
943.788 M
YIELD 
N/A
SHARES OUTSTANDING 
17.757 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.83
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$483,866
AVERAGE 30 VOLUME 
$351,040
Company detail
CEO: Marcio Souza
Region: US
Website: praxismedicines.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression.

Recent news